Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.

Clario的精确MotionOpal®可穿戴传感器技术在由UCB Pharma资助的牛津大学研究中检测早期帕金森病（PD）进展。

Digital endpoints of gait and balance, captured during a 2-Minute Walk test and 30-second Sway test, identify significant motor symptom progression more rapidly than conventional clinical rating scales.

在2分钟步行测试和30秒摇摆测试期间捕获的步态和平衡的数字终点比传统的临床评定量表更快地识别显着的运动症状进展。

Earlier detection supported by state-of-the-art sensor technology and machine learning is a promising discovery to aid in the expedited development of effective PD treatments.

由最先进的传感器技术和机器学习支持的早期检测是一个有希望的发现，有助于加速开发有效的PD治疗。

PHILADELPHIA, Oct. 27, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, today announced that the application of Opal® wearable sensor technology (legacy APDM, Inc.), with advisory from Precision Motion scientists, has helped the University of Oxford researchers develop a new understanding of motor symptom progression in Parkinson's Disease, offering promising implications for neuroscience clinical trials and future treatments..

费城，2023年10月27日/PRNewswire/-Clario，一家为临床试验提供领先终点技术解决方案的医疗保健研究技术公司，今天宣布应用Opal®可穿戴传感器技术（legacy APDM，Inc.），来自Precision Motion科学家的咨询，帮助牛津大学的研究人员对帕金森病的运动症状进展有了新的认识，为神经科学临床试验和未来的治疗提供了有希望的启示。。

Through a comprehensive study leveraging Clario's wearable sensors and machine learning, researchers were able to track the motor symptom progression in individuals with Parkinson's Disease (PD) better than the conventionally used clinical rating scales. Importantly, they found that the wearable technology detected disease progression in a significantly shorter timeframe than the traditional method..

通过利用Clario可穿戴传感器和机器学习的综合研究，研究人员能够比传统使用的临床评定量表更好地跟踪帕金森病（PD）患者的运动症状进展。重要的是，他们发现可穿戴技术在比传统方法短得多的时间内检测到疾病进展。。

Clario's scientific and technical expertise empowered the reliable collection of precise digital endpoints of movement enabling earlier detection of disease progression. This ultimately should accelerate the development of new medicines for PD, and potentially allow for earlier intervention for patients afflicted with this debilitating condition..

Clario的科学和技术专业知识有助于可靠地收集精确的运动数字终点，从而能够及早发现疾病进展。这最终应该加速PD新药的开发，并可能允许对患有这种使人衰弱的疾病的患者进行早期干预。。

The University of Oxford study, led by Chrystalina Antoniades, Associate Professor of Neuroscience, Clinical Neurology, is a part of the Oxford Quantification in Parkinsonism (OxQUIP) project, in which Clario's Precision Motion Opal wearable sensors have been deployed to capture motor impairment in both PD and Progressive Supranuclear Palsy (PSP)..

牛津大学的研究由临床神经病学神经科学副教授Chrystalina Antoniades领导，是牛津帕金森病量化（OxQUIP）项目的一部分，其中Clario的精确运动蛋白石可穿戴传感器已被用于捕获运动损伤PD和进行性核上性麻痹（PSP）。。

'We are honored to support Professor Antoniades with her pivotal research and are very excited about the positive implications of these results on the Parkinsonism field,' said Kristen Sowalsky, PhD, DC, VP of Medical & Scientific Affairs. 'This breakthrough demonstrates the essential benefit of using wearable technology and machine learning algorithms to track Parkinson's Disease progression more accurately and assess the efficacy of early therapeutic intervention.

“我们很荣幸支持Antoniades教授的关键性研究，并对这些结果对帕金森病领域的积极影响感到非常兴奋，”医学和科学事务副总裁Kristen Sowalsky博士说这一突破证明了使用可穿戴技术和机器学习算法更准确地跟踪帕金森病进展并评估早期治疗干预效果的基本益处。

The potential impact of these findings for neuroscience clinical trials is outstanding.'.

这些发现对神经科学临床试验的潜在影响非常突出。

'Time is crucial in clinical trials,' said Professor Antoniades, Associate Professor of Neuroscience, Clinical Neurology at the University of Oxford. 'If we can tell whether a treatment is working earlier, we can speed up its translation. It is also important to be able to tell rapidly which things are not working, so we can divert resources to more promising targets.'.

牛津大学临床神经病学神经科学副教授安东尼亚德斯教授说：“时间在临床试验中至关重要。”如果我们能判断治疗是否提前进行，我们可以加快翻译速度。能够快速判断哪些事情不起作用也很重要，因此我们可以将资源转移到更有希望的目标上。

For direct inquiries, please contact [email protected].

如需直接查询，请联系[电子邮件保护]。

For more information or to speak to a specialist about Clario's Precision Motion data endpoint collection and its ability to transform clinical trials please go to https://clario.com/solutions/precision-motion/.

有关Clario精确运动数据终点收集及其转化临床试验能力的更多信息或与专家交谈，请访问https://clario.com/solutions/precision-motion/.

About Clario

关于克拉罗

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives.

Clario是一家领先的医疗保健研究和技术公司，为我们的制药，生物技术和医疗器械合作伙伴提供行业中最丰富的临床证据。通过分散，混合和基于现场的试验，我们深入的科学专业知识，全球规模和行业最广泛的终点技术平台使我们的合作伙伴能够改变生活。

Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario's global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory approvals for over five million patients in 120 countries.

Clario是唯一结合eCOA，心脏安全，医学成像，精确运动和呼吸终点的技术平台。Clario的全球科学，技术和运营专家团队在9个国家拥有30个设施，帮助为120个国家的500多万患者提供了19000多项试验和870项监管批准。

Our innovation has been transforming clinical trials for 50 years..

我们的创新已经改变了临床试验50年。。

For more information, go to Clario.com or follow us on LinkedIn and Twitter

欲了解更多信息，请访问Clario.com或在LinkedIn和Twitter上关注我们

Clario Media ContactDuncan CantorSr. Director, Corporate Communications[email protected]

Clario Media ContactDuncan CantorSr。公司通讯总监[电子邮件保护]

SOURCE Clario

源Clario